Maraviroc
- Generic Name
- Maraviroc
- Brand Names
- Celsentri, Selzentry
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41F2N5O
- CAS Number
- 376348-65-1
- Unique Ingredient Identifier
- MD6P741W8A
- Background
Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
- Indication
Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.
- Associated Conditions
- CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2019-10-31
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 13
- Registration Number
- NCT01348763
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1
- Conditions
- HIV-1
- Interventions
- Drug: Emtricitabine/tenofovirDrug: placebo for emtricitabine/tenofovirDrug: darunavir/ritonavir 800/100 mg
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 813
- Registration Number
- NCT01345630
- Locations
- 🇺🇸
Circle CARE Center, Norwalk, Connecticut, United States
🇫🇷CHU de Nantes - Hotel Dieu, Nantes, France
🇺🇸Health Services Center, Hobson City, Alabama, United States
A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2017-12-06
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 138
- Registration Number
- NCT01327547
- Locations
- 🇺🇸
AIDS Research Alliance, Los Angeles, California, United States
🇺🇸Georgia Regents Medical Center, Augusta, Georgia, United States
🇺🇸Saint Michael's Medical Center, Newark, New Jersey, United States
Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2011-06-29
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 28
- Registration Number
- NCT01290211
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
Effects of Maraviroc (MVC) on HIV-related Kaposi's Sarcoma (KS)
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 13
- Registration Number
- NCT01276236
- Locations
- 🇺🇸
San Francisco General Hospital, Clinical Trials Unit, San Francisco, California, United States
A Safety and Pharmacokinetic Study for Dapivirine and Maraviroc Gel in Belgium
- Conditions
- HIV Infections
- Interventions
- Drug: Matching Placebo GelDrug: Maraviroc/Dapivirine Gel
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2011-09-09
- Lead Sponsor
- International Partnership for Microbicides, Inc.
- Registration Number
- NCT01242579
Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 60
- Registration Number
- NCT01235013
- Locations
- 🇪🇸
Hospital Clínic i Provincial, Barcelona, Spain
PK Switch Efavirenz to Maraviroc in Patients Initially Suppressed on an Efavirenz-containing Regimen
- First Posted Date
- 2010-08-27
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 12
- Registration Number
- NCT01190293
- Locations
- 🇬🇧
St Stephen's Centre, London, United Kingdom
Effects of Intensive cART During Acute/Early HIV Infection
- Conditions
- Acute HIV Infection
- Interventions
- First Posted Date
- 2010-07-01
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- University of Toronto
- Target Recruit Count
- 32
- Registration Number
- NCT01154673
- Locations
- 🇨🇦
University of Toronto, Toronto, Ontario, Canada
🇨🇦Maple Leaf Medical Clinic, Toronto, Ontario, Canada
Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2011-02-04
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 14
- Registration Number
- NCT01140412
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.